Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia.Correlation with progressive disease

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Huergo Zapico, Leticia ^a   Acebes Huerta, Andrea ^a   Gonzalez Rodriguez, Ana Pilar ^b   Contesti, Juan ^c   Gonzalez Garcia, Esther ^c   Payer, Angel R ^b   Villa Alvarez, Monica ^a   Fernández Guizán, Azahara ^a   López Soto, Alejandro ^a   Gonzalez, Segundo ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c HOSPITAL DE CABUEÑES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 5; LENALIDOMIDE; NATURAL KILLER CELL RECEPTOR NKG2D; IMMUNOLOGIC FACTOR; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL POPULATION; CELLULAR DISTRIBUTION; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXICITY TEST; DOWN REGULATION; FEMALE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROSPECTIVE STUDY; UPREGULATION; AGED; B LYMPHOCYTE; CELL MEMBRANE; CELL PROLIFERATION; CYTOTOXICITY; DISEASE COURSE; DRUG EFFECTS; IMMUNOLOGY; K562 CELL LINE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; PATHOLOGY; PROGNOSIS;

AGED; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL MEMBRANE; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; K562 CELLS; KILLER CELLS, NATURAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE COUNT; MALE; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PROGNOSIS;

EID: 84907741267     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108326     Document Type: Article

References (34)

1. Puente XS, Pinyol M, Quesada V, Conde L, Ordóñez GR, et al. (2011) Wholegenome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475: 101-105. doi: 10.1038/naturel0113
2. Herishanu Y, Katz B-Z, Lipsky A, Wiestner A (2013) Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol Oncol Clin North Am 27: 173-206. doi:10.1016/ j.hoc.2013.01.0024
3. Ramsay AG, Johnson AJ, Lee AM, Görgün G, Le Dieu R, et al. (2008) Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 118: 2427 -2437. doi: 10.1172/JCI35017
4. Gonzalez-Rodriguez AP, Contesti J, Huergo-Zapico L, Lopez-Soto A, Fernández-Guizán A, et al. (2010) Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia. Leuk Lymphoma 51: 1829-1836. doi: 10.3109/10428194.2010.503820
5. Palmer S, Hanson CA, Zent CS, Porrata LF, LaPlant B, et al. (2008) The Prognostic Importance of T and NK-cells in a Consecutive Series of Newly Diagnosed Patients with Chronic Lymphocytic Leukaemia. Br J Haematol 141: 607-614.
6. Poggi A, Venturino C, Catellani S, Clavio M, Miglino M, et al. (2004) Vδ1 T Lymphocytes from B-CLL Patients Recognize ULBP3 Expressed on Leukemic B Cells and Up-Regulated by Trans-Retinoic Acid. Cancer Res 64: 9172-9179. doi: 10.1158/0008-5472.CAN-04-2417
7. Hamblin AD, Hamblin TJ (2008) The immunodeficiency of chronic lymphocytic leukaemia. Br Med Bull 87: 49-62. doi: 10.1093/bmb/ldn034
8. Huergo-Zapico L, Acebes-Huerta A, López-Soto A, Villa-Alvarez M, Gonzalez-Rodriguez AP, et al. (2014) Molecular Bases for the Regulation of NKG2D Ligands in Cancer. Front Immunol 5: 106. doi:10.3389/fimmu.2014.00106
9. López-Soto A, Huergo-Zapico L, Acebes-Huerta A, Villa-Alvarez M, Gonzalez S (2014) NKG2D signaling in cancer immunosurveillance. Int J Cancer, doi: 10.1002/ijc. 28775
10. Gasser S, Orsulic S, Brown EJ, Raulet DH (2005) The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436: 1186-1190. doi: 10.1038/nature03884
11. Smyth MJ, Swann J, Cretney E, Zerafa N, Yokoyama WM, et al. (2005) NKG2D function protects the host from tumor initiation. J Exp Med 202: 583-588. doi: 10.1084/jem.20050994
12. Sutherland CL, Rabinovich B, Chalupny NJ, Brawand P, Miller R, et al. (2006) ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15. Blood 108: 1313-1319. doi:10.1182/blood-2005-11-011320
13. Nückel H, Switala M, Sellmann L, Horn PA, Dürig J, et al. (2010) The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. Leukemia 24: 1152-1159. doi:10.1038/leu.2010.74
14. Groh V, Wu J, Yee C, Spies T (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419: 734-738. doi: 10.1038/nature01 112
15. Huergo-Zapico L, Gonzalez-Rodriguez AP, Contesti J, Gonzalez E, López-Soto A, et al. (2012) Expression of ERp5 and GRP78 on the membrane of chronic lymphocytic leukemia cells: association with soluble MICA shedding. Cancer Immunol Immunother 61: 1201-1210. doi:10.1007/s00262-011-1195-z
16. Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, et al. (2002) CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99: 1023-1029.
17. Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, et al. (2001) Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 98: 579-585.
18. Behl D, Porrata LF, Markovic SN, Letendre L, Pruthi RK, et al. (2006) Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 20: 29-34. doi:10.1038/ sj.leu.2404032
19. Siddiqui M, Ristow K, Markovic SN, Witzig TE, Habermann TM, et al. (2006) Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol 134: 596-601. doi: 10.1111/j. 1365-2141.2006.06232.x
20. Cox MG, Nofroni I, Ruco L, Amodeo R, Ferrari A, et al. (2008) Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma 49: 1745-1751. doi:10.1080/10428190802226425
21. Porrata LF, Ristow K, Habermann TM, Witzig TE, Inwards DJ, et al. (2009) Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma. Am J Hematol 84: 93-97. doi: 10.1002/ajh.21337
22. Ege H, Gertz MA, Markovic SN, Lacy MQ, Dispenzieri A, et al. (2008) Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study. Br J Haematol 141: 792 -798. doi: 10.1111/j.l365-2141.2008.07123.x
23. Plonquet A, Haioun G, JaisJ-P, Debard A-L, Salles G, et al. (2007) Peripheral blood natural killer cell count is associated with clinical outcome in patients with aalPI 2-3 diffuse large B-cell lymphoma. Ann Oncol 18: 1209-1215. doi: 10.1093/annonc/mdml 10
24. Te Raa GD, Tonino SH, Remmerswaal EBM, van Houte AJ, Koene HR, et al. (2012) Chronic lymphocytic leukemia specific T-cell subset alterations are clonesize dependent and not present in monoclonal B lymphocytosis. Leuk Lymphoma 53: 2321-2325. doi:10.3109/10428194.2012.698277
25. Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21: 137-148. doi:10.1016/ j.immuni. 2004.07.017
26. Kay NE, Zarling JM (1984) Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood 63: 305-309.
27. Reiners KS, Topolar D, Henke A, Simhadri VR, Kessler J, et al. (2013) Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity. Blood 121: 3658-3665. doi: 10.1182/ blood-2013-01-476606
28. Groh V, Smythe K, Dai Z, Spies T (2006) Fas ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity. Nat Immunol 7: 755 -762. doi:10.1038/nil350
29. Allez M, Tieng V, Nakazawa A, Treten X, Pacault V, et al. (2007) CD4+ NKG2D+ T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions. Gastroenterology 132: 2346-2358. doi: 10.1053/j. gastro. 2007.03.025
30. Dai Z, Turde CJ, Booth GG, Riddell SR, Cooley TA, et al. (2009) Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus. J Exp Med 206: 793 -805. doi:10.1084/jem.20081648
31. Veuillen C, Aurran-Schleinitz T, Castellano R, Rey J, Mallet F, et al. (2012) Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy. J Clin Immunol 32: 632-646. doi:10.1007/s10875-011-9624-5
32. Eskelund GW, Nederby L, Thysen AH, Skovbo A, Roug AS, et al. (2011) Interleukin-21 and rituximab enhance NK cell functionality in patients with B-cell chronic lymphocytic leukaemia. Leuk Res 35: 914-920. doi:10.1016/ j.leukres.2011.02.006
33. Awan FT, Johnson AJ, Lapalombella R, Hu W, Lucas M, et al. (2010) Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 51: 27-38. doi: 10.3109/ 10428190903350405
34. Takaki R, Hayakawa Y, Nelson A, Sivakumar PV, Hughes S, et al. (2005) IL-21 enhances tumor rejection through a NKG2D-dependent mechanism. J Immunol 175: 2167-2173.